Celldex Therapeutics Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $1.61 billion
- Book Value:
- Revenue TTM:
- $3.15 million
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Celldex Therapeutics Inc had its IPO on 2008-03-10 under the ticker symbol CLDX.
The company operates in the Healthcare sector and Biotechnology industry. Celldex Therapeutics Inc has a staff strength of 148 employees.
Shares of Celldex Therapeutics Inc opened at $27.5 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $27.17 - $28.04, and closed at $27.63.
This is a +0.36% increase from the previous day's closing price.
A total volume of 246,495 shares were traded at the close of the day’s session.
In the last one week, shares of Celldex Therapeutics Inc have slipped by -4.1%.
Celldex Therapeutics Inc's Key Ratios
Celldex Therapeutics Inc has a market cap of $1.61 billion, indicating a price to book ratio of 5.0657 and a price to sales ratio of 1935.1115.
In the last 12-months Celldex Therapeutics Inc’s revenue was $3.15 million with a gross profit of $-79901000 and an EBITDA of $-112963000. The EBITDA ratio measures Celldex Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Celldex Therapeutics Inc’s operating margin was -3675.37% while its return on assets stood at -19.33% with a return of equity of -33.86%.
In Q1, Celldex Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 455.7%.
Celldex Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-2.64 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Celldex Therapeutics Inc’s profitability.
Celldex Therapeutics Inc stock is trading at a EV to sales ratio of 1326.4524 and a EV to EBITDA ratio of -16.2809. Its price to sales ratio in the trailing 12-months stood at 1935.1115.
Celldex Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $324.52 million
- Total Liabilities
- $15.22 million
- Operating Cash Flow
- $52.57 million
- Capital Expenditure
- Dividend Payout Ratio
Celldex Therapeutics Inc ended 2023 with $324.52 million in total assets and $0 in total liabilities. Its intangible assets were valued at $324.52 million while shareholder equity stood at $302.74 million.
Celldex Therapeutics Inc ended 2023 with $0 in deferred long-term liabilities, $15.22 million in other current liabilities, 47000.00 in common stock, $-1285293000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $54.12 million and cash and short-term investments were $278.39 million. The company’s total short-term debt was $1,493,000 while long-term debt stood at $0.
Celldex Therapeutics Inc’s total current assets stands at $289.60 million while long-term investments were $0 and short-term investments were $224.26 million. Its net receivables were $1.31 million compared to accounts payable of $3.37 million and inventory worth $0.
In 2023, Celldex Therapeutics Inc's operating cash flow was $52.57 million while its capital expenditure stood at $585000.
Comparatively, Celldex Therapeutics Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Celldex Therapeutics Inc stock is currently trading at $27.63 per share. It touched a 52-week high of $48.4 and a 52-week low of $48.4. Analysts tracking the stock have a 12-month average target price of $66.33.
Its 50-day moving average was $32.49 and 200-day moving average was $37.11 The short ratio stood at 9.21 indicating a short percent outstanding of 0%.
Around 30.7% of the company’s stock are held by insiders while 10554.8% are held by institutions.
Frequently Asked Questions About Celldex Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company’s clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company’s proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. It has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.